Human organoids-on-chips (OrgOCs) represent a revolutionary approach that combines human organoids (HOs) technology with microfluidic organs-on-chips (OOCs), aiming to create 3D organotypic living models that mimic the crucial tissue-specific properties of human organs. This innovative technology bridges the gap between traditional 2D cell cultures and animal models by offering more accurate representations of human biology. OrgOCs have shown great promise in various fields including basic biology, disease modeling, preclinical assays, and precision medicine. By leveraging advancements in biomaterials, chemistry, computer science, and mathematics, scientists have been able to create reliable human organ models that have garnered global attention.
OOCs serve asin vitromicrophysiological systems that replicate essential microenvironment parameters of living organs, such as biochemical and physical factors, enabling the modeling of organ-level ‘synthetic biology’. On the other hand, HOs, derived from human pluripotent stem cells or adult stem cells, recapitulate biological parameters and cell interactions crucial for organogenesis. The integration of OOCs and HOs in OrgOCs provides a platform for studying organ development, host-immune responses, and drug-organ interactions. These systems offer a unique opportunity to investigate human biology in a controlled environment, facilitating a better understanding of organ physiology and pathology.
Advances in OrgOCs technology have led to breakthroughs in modeling human organ development and disease states. Researchers have successfully mimicked the folding dynamics of human brain organoids and the peristalsis traits of gastrointestinal organoids, shedding light on the mechanical factors influencing organ development. Spatial confinement within OrgOCs has been utilized to guide organoid morphogenesis, enabling the formation of structures resembling natural organs. By incorporating dynamic fluid flow and 3D topography architecture, OrgOCs can promote cell proliferation, reduce apoptosis, and enhance organoid maturation, offering a more physiological microenvironment for studying organ development and function.
The heterogeneity and limitations of traditional organoid models have been addressed through innovative OrgOCs approaches. Microwell structures, droplet microfluidics, and 3D bioprinting technologies have been employed to create uniform organoids with reduced variability, enhancing the reliability of experimental results. Integration of sensing elements, artificial intelligence, and multi-omics analysis in OrgOCs systems allows for real-time monitoring and analysis of biological signals, advancing drug efficacy prediction and safety assessments. While OrgOCs have not yet fully replicated the complexity of native human organs, they have demonstrated significant potential in reducing the reliance on animal models and improving preclinical drug testing.
In conclusion, the remarkable progress in OrgOCs technology has opened new frontiers in biomedical research, offering unprecedented opportunities for studying human organ development, disease modeling, and precision medicine. By combining the strengths of OOCs and HOs, OrgOCs provide a powerful platform for investigating organ-level functions and interactions in a controlled environment. While challenges remain in achieving fully representative human organ models, the ongoing advancements in OrgOCs hold great promise for enhancing our understanding of human biology and accelerating the development of novel therapies.
- OrgOCs technology combines HOs and OOCs to create 3D organotypic models that mimic human organ properties.
- OOCs replicate microenvironment factors, while HOs recapitulate biological parameters critical for organogenesis.
- Advances in OrgOCs have enabled modeling of human organ development and disease states with improved accuracy.
- Innovative approaches such as microwell structures and 3D bioprinting have addressed heterogeneity issues in organoid models.
Tags: secretion, cell culture, regulatory, automation, quality control, synthetic biology, clinical trials, mass spectrometry, immunotherapy, cell therapy
Read more on pmc.ncbi.nlm.nih.gov
